Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BCL6 | P41182 | 2/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318945 | 0.87 | TNF (0.44) | DHFRTNFPIK3CAGRM4NPSR1 | |
| SCHEMBL6313731 | 0.86 | PIK3CA (0.41) | DHFRADORA2AADORA1TNFPIK3CA | |
| SCHEMBL6315288 | 0.85 | PDGFRB (0.49) | ADORA2AADORA1TNFPIK3CAGRM4 | |
| SCHEMBL6319736 | 0.84 | CDC7 (0.47) | DHFRTNFPIK3CAGRM4 | |
| SCHEMBL6312244 | 0.83 | CYP1A2 (0.52) | ADORA2AADORA1TNFPIK3CAKDM4E | |
| SCHEMBL6313258 | 0.83 | DYRK1A (0.43) | DHFRADORA2AADORA1TNFPIK3CA | |
| SCHEMBL6312550 | 0.83 | CA12 (0.56) | TNFPIK3CAGRM4KDM4EKDR | |
| SCHEMBL6320672 | 0.82 | MAPT (0.50) | DHFRPIK3CANPSR1 | |
| SCHEMBL6313300 | 0.82 | ABCG2 (0.46) | DHFRADORA2AADORA1TNFPIK3CA | |
| SCHEMBL6315310 | 0.82 | ADORA1 (0.45) | DHFRADORA2AADORA1TNFPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | claimed |
| US-6939874-B2 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | AMGEN INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063705-A1 | Substituted pyrimidinyl derivatives and methods of use | DPYD, TYMP, TPMT | DHFR 4/4885ADORA2A 302/4885ADORA1 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.